Optimal Dosing Strategies for Moderate ADHD

Introduction to Dose Optimization

The American Academy of Pediatrics guidelines emphasize that stimulant response is variable and unpredictable, requiring titration from a low dose to one that achieves maximum optimal effect without adverse effects, with over 70% of patients requiring dose optimization beyond the starting dose to achieve maximum benefit 1, 2
Calculating dose based on mg/kg has not been helpful, as dose variations are not reliably related to height or weight, and titration can be accomplished rapidly—effectively on a 7-day basis, or in urgent situations, as few as 3 days 1, 2

Multiple international guidelines establish that Concerta is available in 18, 27, 36, and 54 mg formulations, with maximum daily doses ranging from 54-72 mg depending on the country and age group, and the typical dosing progression is 18 mg → 27 mg → 36 mg → 54 mg (and potentially 72 mg in some populations) 3, 4
Japan's guidelines specify a maximum of 54 mg/day for OROS-MPH (Concerta), while Malaysia, India, and Republic of Korea guidelines indicate maximum doses of 72 mg/day 3, 4

The landmark MTA study demonstrated that systematic dose titration across multiple dose levels resulted in over 70% of children and adolescents responding to methylphenidate when the full range of doses was administered, and revealed that children receiving "community treatment as usual" showed less beneficial results compared to those receiving optimal medication management 1, 2
The MTA study finding is particularly relevant, as staying at 18 mg without titration mirrors the suboptimal community treatment approach, and the goal should be reducing core symptoms to or close to the levels of children without ADHD, which typically requires doses higher than 18 mg 1, 2

Start at 18 mg Concerta once daily in the morning, and assess response after 7 days using standardized rating scales, then increase to 27 mg for 7 days, and reassess, continuing titration in 9-18 mg increments weekly until maximum benefit is achieved, intolerable side effects emerge, or maximum dose is reached 1, 5
Monitor for common adverse effects, and avoid accepting suboptimal symptom control at lower doses due to concerns about side effects or a belief that "some improvement" is sufficient, as the most common error is accepting suboptimal symptom control at lower doses 1, 2